NZ336073A - Crystal form 0 of clarithromycin as treatment for gram-positive bacteria, some gram-negative bacteria, mycoplasma and chlamidia - Google Patents

Crystal form 0 of clarithromycin as treatment for gram-positive bacteria, some gram-negative bacteria, mycoplasma and chlamidia

Info

Publication number
NZ336073A
NZ336073A NZ336073A NZ33607397A NZ336073A NZ 336073 A NZ336073 A NZ 336073A NZ 336073 A NZ336073 A NZ 336073A NZ 33607397 A NZ33607397 A NZ 33607397A NZ 336073 A NZ336073 A NZ 336073A
Authority
NZ
New Zealand
Prior art keywords
gram
chlamidia
clarithromycin
mycoplasma
treatment
Prior art date
Application number
NZ336073A
Other languages
English (en)
Inventor
Stephen G Spanton
Rodger F Henry
David A Riley
Jih-Hua Liu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25136084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ336073(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NZ336073A publication Critical patent/NZ336073A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NZ336073A 1997-01-17 1997-12-19 Crystal form 0 of clarithromycin as treatment for gram-positive bacteria, some gram-negative bacteria, mycoplasma and chlamidia NZ336073A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/785,623 US5945405A (en) 1997-01-17 1997-01-17 Crystal form O of clarithromycin
PCT/US1997/023607 WO1998031699A1 (en) 1997-01-17 1997-12-19 Crystal form 0 of clarithromycin

Publications (1)

Publication Number Publication Date
NZ336073A true NZ336073A (en) 2001-01-26

Family

ID=25136084

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ336073A NZ336073A (en) 1997-01-17 1997-12-19 Crystal form 0 of clarithromycin as treatment for gram-positive bacteria, some gram-negative bacteria, mycoplasma and chlamidia

Country Status (18)

Country Link
US (1) US5945405A (OSRAM)
EP (1) EP1077988A1 (OSRAM)
JP (3) JP4058114B2 (OSRAM)
KR (1) KR100567149B1 (OSRAM)
CN (1) CN1174991C (OSRAM)
AR (3) AR011077A1 (OSRAM)
AU (1) AU735598B2 (OSRAM)
BR (1) BR9714287A (OSRAM)
CA (4) CA2387356C (OSRAM)
CZ (1) CZ297433B6 (OSRAM)
DE (1) DE97951771T1 (OSRAM)
ES (1) ES2173058T1 (OSRAM)
IL (1) IL130255A0 (OSRAM)
NZ (1) NZ336073A (OSRAM)
TR (1) TR199901578T2 (OSRAM)
TW (1) TW574224B (OSRAM)
WO (1) WO1998031699A1 (OSRAM)
ZA (1) ZA98116B (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
GB9827355D0 (en) * 1998-12-11 1999-02-03 Biochemie Sa Organic compounds
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
US6627743B1 (en) * 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
PT1254146E (pt) * 1999-12-16 2005-10-31 Teva Pharma Processos de preparacao de polimeros de claritromicina e novo polimorfo iv
FR2802534B1 (fr) * 1999-12-20 2002-02-01 Merial Sas Procede pour preparer et isoler la 9-deoxo-9 (z)- hydroxyiminoerythromycine a
PL356645A1 (en) * 2000-01-11 2004-06-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AU2578701A (en) 2000-02-29 2001-09-12 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
CN1193036C (zh) * 2000-03-15 2005-03-16 韩美药品工业株式会社 制备甲红霉素－克拉霉素ⅱ型晶体的方法
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
WO2002011768A1 (en) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
WO2005039531A1 (en) * 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
RU2217160C2 (ru) * 2001-04-20 2003-11-27 Челябинская государственная медицинская академия Способ местного лечения урогенитального хламидиоза у женщин
EP1411899B1 (en) * 2001-08-01 2009-03-11 Novartis AG Taste masking composition
TW200302830A (en) * 2002-01-11 2003-08-16 Chugai Pharmaceutical Co Ltd Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
CN100427498C (zh) * 2003-03-02 2008-10-22 王凌峰 克拉霉素a型结晶
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648418A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
EP1648415A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1658034A4 (en) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
DE102007016367A1 (de) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
EP2030613A1 (en) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS5782400A (en) 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
DE3782994T2 (de) * 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
JPH0755958B2 (ja) * 1986-10-03 1995-06-14 大正製薬株式会社 エリスロマイシンａ誘導体の製造方法
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
JP2526951B2 (ja) * 1986-12-17 1996-08-21 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
JP2751385B2 (ja) * 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
PT915899E (pt) * 1996-07-29 2004-11-30 Abbott Lab Preparacao da forma cristalina ii da eritromicina
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin

Also Published As

Publication number Publication date
CZ242699A3 (cs) 1999-11-17
JP5190350B2 (ja) 2013-04-24
AR039667A2 (es) 2005-03-02
US5945405A (en) 1999-08-31
ZA98116B (en) 1998-07-08
CA2419499A1 (en) 1998-07-23
AR039666A2 (es) 2005-03-02
JP2000509725A (ja) 2000-08-02
AU5532698A (en) 1998-08-07
JP2004075689A (ja) 2004-03-11
CN1244869A (zh) 2000-02-16
IL130255A0 (en) 2000-06-01
KR20000070220A (ko) 2000-11-25
EP1077988A1 (en) 2001-02-28
WO1998031699A1 (en) 1998-07-23
BR9714287A (pt) 2000-04-18
CA2277274C (en) 2003-05-27
KR100567149B1 (ko) 2006-04-04
CA2277274A1 (en) 1998-07-23
CZ297433B6 (cs) 2006-12-13
CA2387361C (en) 2003-05-27
DE97951771T1 (de) 2004-07-08
CA2387361A1 (en) 1998-07-23
CA2387356A1 (en) 1998-07-23
JP2009137975A (ja) 2009-06-25
TW574224B (en) 2004-02-01
JP4058114B2 (ja) 2008-03-05
CN1174991C (zh) 2004-11-10
ES2173058T1 (es) 2002-10-16
AU735598B2 (en) 2001-07-12
TR199901578T2 (xx) 1999-09-21
AR011077A1 (es) 2000-08-02
CA2387356C (en) 2003-05-27

Similar Documents

Publication Publication Date Title
ES2173058T1 (es) Forma cristalina o de claritromicina.
IE782421L (en) Pleuromutilin glycosides
NZ335825A (en) Use of azithromycin for treating atherosclerosis
IE832652L (en) Derivatives of epimeric azahomoerythromycin.
BR9306741A (pt) Derivados de macrólidos antibióticos com anel de 16 membros
MD970243A (en) 9-O-Oximes erythromycin A derivatives, possessing antibiotic properties
Omura et al. Communications to the editor Chimeramycins: New Macrolide Antibiotics produced by Hybrid biosynthesis
IE812616L (en) Macrolide antibiotic
CA2191920A1 (en) Derivatives of 3-deoxy 16-membered ring macrolide antibiotics
AU551064B2 (en) Macrolide antibiotics for controlling pasteurella infections
KR100360568B1 (en) 16-membered ring macrolide derivative and method for manufacturing the same
MY133360A (en) Diphosphate salt of a "4" -substituted-9-deoxo-9a-aza-9a-homoerythromycin derivative and its pharmaceutical composition
EP0682038A4 (en) 5-0-DESOSAMINYLERYTHRONOLIDE DERIVATIVE.
AU3121095A (en) Antibiotic macrolides
WO2000040589A3 (en) Novel derivatives from the class of oleandomycin
ES8207218A1 (es) Un procedimiento para la preparacion de un antibiotico macrolida.
AU2617584A (en) Macrolide ptl-448-a,b,c and d
AU6535680A (en) Antibiotic from streptomyces
AU6152994A (en) Novel polyketide antibiotics from streptomyces venezuelae
ES2191778T3 (es) Derivados de 3-desoxi-3-descladinosa de las eritromicinas a y b.
NO950143L (no) Derivater av antibiotiske makrolider med 16-leddet ring
MX9605773A (es) Compuestos de cefalosporina y procesos para la preparacion de los mismos.
CA2419729A1 (en) Crystal form ii of clarithromycin
CA2471102A1 (en) Crystal form ii of clarithromycin
JPS548792A (en) Novel preparation of ribostamycin

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: BGP PRODUCTS OPERATIONS GMBH, CH

Effective date: 20160324

EXPY Patent expired